Victor Micati

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Origin Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of a plasma device that generate nitric oxide (NO) in the form of a plasma or NO stream. It focuses on its IonoJet platform, which provides therapeutic treatments which helps in immune system and blood vessel regulation, and tissue regeneration. The company was founded by Michael D. Preston and Alexander Dolgopolsky on June 14, 2010 and is headquartered in Princeton, NJ.

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.